Evidence map›Paper›PMID 35582028›Full record

ReviewCancer drug resistance (Alhambra, Calif.)2021

History of intraperitoneal platinum drug delivery for ovarian cancer and its future applications.

Franco Muggia, Andrea Bonetti

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer drug resistance (Alhambra, Calif.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Oxaliplatin-induced peripheral neuropathy: from pathogenesis to treatment.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Review
  2. Review
  3. Article
  4. Tackling cisplatin resistance in ovarian cancer: what can we do?Cancer drug resistance (Alhambra, Calif.) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Franco MuggiaDepartment of Medical Oncology, New York University Langone Health, New York, NY 10016, USA.
Andrea BonettiDepartment of Medical Oncology, Mater Salutis Hospital, AULSS 9 of the Veneto Region, Legnago (VR) 37121, Italy.
ATS Sardegna (Italy) · ITNYU Langone Health · US

Funding

Symposium on Hereditary Breast & Ovarian Cancers: Risk and ChallengesR13CA142030 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MUGGIA, FRANCO · 2009 to 2009
$13k
Symposium on Hereditary Breast and Ovarian Cancers: Lessening the BurdeR13CA162868 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MUGGIA, FRANCO · 2011 to 2011
$5k
NCI NIH HHS R13 CA142030NCI NIH HHS R13 CA162868
6 · The paper itself

Abstract

Intraperitoneal (IP) delivery of cisplatin was developed in the 1970s based on a strong pharmacologic rationale and rodent models. Its advantage over intravenous (IV) administration was supported initially by observational studies in treating recurrent ovarian cancer and eventually by better outcomes from IP

Indexed as

epithelial ovarian carcinomaintraperitoneal administrationPlatinum drugs

Identifiers

PMID35582028
PMCPMC9019271
OpenAlexW3137470891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.